Wasatch Advisors LP reduces shareholding in Vijaya Diagnostic Centre Ltd to 3.746%

1 min read     Updated on 21 Feb 2026, 12:30 PM
scanx
Reviewed by
Riya DScanX News Team
Overview

Wasatch Advisors LP has reduced its stake in Vijaya Diagnostic Centre Ltd by selling 23,608 shares through open market transactions on February 19, 2026. The sale decreased the US investment firm's shareholding from 3.769% to 3.746%, leaving it with 3,854,484 shares. The transaction was disclosed under SEBI SAST regulations, with the firm maintaining its position as a non-promoter institutional investor in the diagnostic services company.

33202835

*this image is generated using AI for illustrative purposes only.

US-based investment firm Wasatch Advisors LP has reduced its shareholding in Vijaya Diagnostic Centre Ltd through an open market transaction, as disclosed under SEBI's Substantial Acquisition of Shares and Takeovers (SAST) Regulations. The disclosure was filed with the National Stock Exchange of India and BSE Limited on February 20, 2026.

Transaction Details

The investment firm sold 23,608 shares of Vijaya Diagnostic Centre Ltd on February 19, 2026, through open market sale. This transaction represents a reduction of 0.023% in the firm's shareholding percentage.

Transaction Parameter: Details
Shares Sold: 23,608
Transaction Date: February 19, 2026
Mode of Sale: Open market
Percentage Reduction: 0.023%

Shareholding Position

Following the share disposal, Wasatch Advisors LP's shareholding in Vijaya Diagnostic Centre Ltd has been adjusted as follows:

Shareholding Details: Before Transaction After Transaction
Number of Shares: 3,878,092 3,854,484
Shareholding Percentage: 3.769% 3.746%
Voting Rights Percentage: 3.769% 3.746%

Company Information

Vijaya Diagnostic Centre Ltd maintains its equity share capital structure with the following parameters:

Capital Structure: Details
Total Equity Share Capital: Rs. 102,896,700.00
Total Issued Shares: 102,896,700
Par Value per Share: Rs. 1.00
Total Diluted Share Capital: 102,896,728.00

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (SAST) Regulations, 2011, which mandates reporting of substantial changes in shareholding. Dan Thurber, VP and General Counsel of Wasatch Advisors LP, signed the disclosure document on behalf of the firm. Wasatch Advisors LP is not part of the promoter or promoter group of Vijaya Diagnostic Centre Ltd.

The shares of Vijaya Diagnostic Centre Ltd are listed on both BSE and NSE, providing liquidity for such institutional transactions. The firm's reduced but continued shareholding indicates ongoing investment interest in the diagnostic services company.

Historical Stock Returns for Vijaya Diagnostic Centre

1 Day5 Days1 Month6 Months1 Year5 Years
-0.06%+1.44%+3.19%-4.32%+8.75%+62.70%
Vijaya Diagnostic Centre
View Company Insights
View All News
like18
dislike

Vijaya Diagnostic Centre Makes Q3FY26 Earnings Call Audio Recording Available

1 min read     Updated on 14 Feb 2026, 12:08 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Vijaya Diagnostic Centre Limited has made available the audio recording of its Q3FY26 earnings conference call held on February 13, 2026, following the release of unaudited financial results for the quarter and nine months ended December 31, 2025. The recording is accessible through a direct link and on the company's website under the investors section, with the disclosure made to NSE and BSE on February 14, 2026, in compliance with Regulation 30 requirements.

32596686

*this image is generated using AI for illustrative purposes only.

Vijaya Diagnostic Centre Limited has announced the availability of the audio recording from its earnings conference call for Q3FY26, held on February 13, 2026. The company made this disclosure to stock exchanges on February 14, 2026, in compliance with Regulation 30 requirements.

Earnings Call Details

The earnings conference call was organized following the declaration of the company's unaudited financial results for the third quarter and nine months ended December 31, 2025. The call provided stakeholders with insights into the company's financial performance and business developments during the reporting period.

Parameter: Details
Call Date: February 13, 2026
Results Period: Q3 and nine months ended December 31, 2025
Disclosure Date: February 14, 2026
Regulation: Regulation 30 compliance

Accessibility and Availability

The audio recording has been made accessible to investors and stakeholders through multiple channels. The company has provided a direct link to access the recording, which is hosted on their cloud storage platform. Additionally, the recording is available on the company's official website for easy access by interested parties.

The recording can be accessed through the company's investor relations section by following the path: Investors > Results Reports & Presentation > Financial Results > FY 2025-26 > Quarter – III.

Regulatory Compliance

This disclosure was made to both the National Stock Exchange of India Limited and BSE Limited as part of the company's regulatory obligations. The communication was signed by Hansraj Singh, Company Secretary & Compliance Officer, ensuring proper authorization and compliance with corporate governance requirements.

Exchange: Symbol/Code
NSE: VIJAYA
BSE: 543350

The availability of the earnings call recording demonstrates the company's commitment to transparency and providing stakeholders with comprehensive access to financial information and management commentary on business performance.

Historical Stock Returns for Vijaya Diagnostic Centre

1 Day5 Days1 Month6 Months1 Year5 Years
-0.06%+1.44%+3.19%-4.32%+8.75%+62.70%
Vijaya Diagnostic Centre
View Company Insights
View All News
like17
dislike

More News on Vijaya Diagnostic Centre

1 Year Returns:+8.75%